• Theriva Biologics posted a Q2 2026 net loss attributable to common stockholders of USD 3.22 million, narrowing from USD 13.06 million a year earlier.
• Operating loss narrowed to USD 3.3 million from USD 13.13 million, as general and administrative expense fell 82% to USD 2.03 million.
• Research and development expense dropped 35% to USD 1.27 million, reflecting lower clinical trial costs, partly offset by higher VCN-01 manufacturing activity.
• Cash and cash equivalents totaled USD 11.34 million at June 30, 2026; management said the cash runway extends into Q1 2027.
• First patients were dosed in the VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC; enrollment is expected in H2 2026 with initial safety data due Q3 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110800OMX_____CNEWS_EN_GNW9807357_en) on August 11, 2026, and is solely responsible for the information contained therein.